Q1 EPS Forecast for iTeos Therapeutics Boosted by Analyst

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Analysts at HC Wainwright raised their Q1 2025 EPS estimates for iTeos Therapeutics in a research note issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.39) for the quarter, up from their prior estimate of ($1.44). HC Wainwright has a “Buy” rating and a $46.00 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for iTeos Therapeutics’ Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.48) EPS, Q4 2025 earnings at ($1.53) EPS, FY2026 earnings at ($5.68) EPS, FY2027 earnings at ($3.46) EPS and FY2028 earnings at ($0.74) EPS.

ITOS has been the subject of a number of other reports. JPMorgan Chase & Co. reduced their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th. Wedbush restated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, Wells Fargo & Company cut their price target on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $7.06 on Monday. The stock has a market capitalization of $269.65 million, a P/E ratio of -2.24 and a beta of 1.38. The company has a 50-day moving average price of $7.51 and a 200-day moving average price of $9.22. iTeos Therapeutics has a 1 year low of $6.67 and a 1 year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13.

Institutional Trading of iTeos Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio raised its position in iTeos Therapeutics by 192.2% in the fourth quarter. Public Employees Retirement System of Ohio now owns 84,220 shares of the company’s stock worth $647,000 after acquiring an additional 55,394 shares during the period. Stonepine Capital Management LLC raised its position in iTeos Therapeutics by 266.7% in the fourth quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock worth $845,000 after acquiring an additional 80,000 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in iTeos Therapeutics in the fourth quarter worth about $42,000. Man Group plc raised its position in iTeos Therapeutics by 34.7% in the fourth quarter. Man Group plc now owns 29,169 shares of the company’s stock worth $224,000 after acquiring an additional 7,516 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in iTeos Therapeutics by 90.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,589 shares of the company’s stock worth $965,000 after acquiring an additional 59,649 shares during the period. Institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.